Stock Financial Ratios


RGRX / RegeneRx Biopharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price0.31
Volume11,100.00
Market Cap ($M)33.13
Enterprise Value ($M)38.79
Book Value ($M)-6.07
Book Value / Share-0.05
Price / Book-5.49
NCAV ($M)0.20
NCAV / Share0.00
Price / NCAV-67.01
Income Statement (mra) ($M)
Revenue0.09
EBITDA-1.67
Net Income0.23
Balance Sheet (mrq) ($M)
Cash & Equivalents0.19
Cash / Share0.00
Assets0.22
Liabilities6.25
Quick Ratio1.29
Current Ratio1.29
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.04
Return on Assets (ROA)0.27
Return on Equity (ROE)-0.04
Identifiers and Descriptors
CUSIP75886X108
Central Index Key (CIK)707511
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Share Statistics
Common Shares Outstanding (M)109.79
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Minority Interest Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Equity Per Share-0.05
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Cash Per Share0.00
Accounts Payable Per Share0.00
Inventory Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Debt Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Liabilities Current Per Share0.01
Cash And Equivalents Per Share0.00
Additional Paid In Capital Per Share0.79
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Retained Earnings Per Share-0.84
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Liabilities Per Share0.05
Assets Current Per Share0.00

Related News Stories

ReGenTree Announces the Results of the ARISE-2 Trial With RGN-259 for the Treatment of Dry Eye: Significant Efficacies Were Confirmed in Both Signs and Symptoms

2017-10-31 accesswire
PRINCETON, NJ / ACCESSWIRE / October 31, 2017 / ReGenTree, LLC, a joint venture between GtreeBNT and RegeneRx, announced today that the Phase 3 clinical trial (ARISE-2) of RGN-259 for the treatment of dry eye has been completed. The ARISE-2 trial investigated the safety and efficacy of RGN-259 compared to placebo for the treatment of the signs and symptoms of dry eye syndrome in 601 patients. (16-0)

My Interview With Shire On The Controversial Dry Eye Market

2017-10-05 seekingalpha
AGN sold its Restasis patents to an Indian Tribe, and now, lawmakers are parsing the dry-eye market. (77-0)

CUSIP: 75886X108